RxDoctor Payments DataLook up a doctor →

Jorge Rivero-Becerra, MD

Interventional Pain Medicine · Pittsburgh, PANPI 1396780409

Payments from drug & device makers

$12,353in general payments, 2019–2025

Across 768 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • Abbott$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Boston Scientific$903
  • Scilex Pharmaceuticals Inc.$859
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$12,334100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,353 in reported general payments places this provider in the 85th percentile of 59 interventional pain medicine providers in Pennsylvania.

See all interventional pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$146,090
Medicare patients
191
Services billed
3,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate156$98,918
OxycontinOxycodone Hcl114$85,847
RelistorMethylnaltrexone Bromide26$58,448
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,927$39,284
MovantikNaloxegol Oxalate92$38,232
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl227$30,593
Buprenorphine78$25,478
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,171$24,764
Oxymorphone Hcl ErOxymorphone Hcl23$17,314
BelbucaBuprenorphine Hcl24$15,405
Gabapentin1,100$15,266
Morphine Sulfate ErMorphine Sulfate425$11,447
Diclofenac Sodium30$10,386
NucyntaTapentadol Hcl12$10,247
Lidocaine70$8,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta$1,763$124,570192 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,335$58,44826 claims
Redhill Biopharma Inc.Movantik$178$38,23292 claims
Indivior Inc.Suboxone$761$5,57411 claims
Orexo US, Inc.Zubsolv$130$3,91816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 interventional pain medicine providers in Pennsylvania.

Other interventional pain medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →